Cycle 3 of Lu-177 DOTATATE in a patient with one kidney, rising creatinine and falling platelets

Grading (CTCAE):

• Platelets 88 x 10^9/L = grade 1 (grade 2 is 50-75, grade 3 is 25-50, grade 4 below 25).
• ANC 1.5 x 10^9/L = grade 2 neutropenia (1.0-1.5).
• eGFR 41 mL/min/1.73 m2 = CKD stage 3b, and the fall from 58 is a decline of about 17 mL/min over two cycles - more informative than the absolute number.

Decision: do not simply repeat 7.4 GBq. Most PRRT protocols require a creatinine clearance around 40-50 mL/min for full activity, and he is at the edge with a documented downward trend and new edema. Blood counts are not the limiting factor - grade 1-2 cytopenias are expected and manageable - but the kidney is solitary and irreplaceable.

Reasonable plan:

1. Look for a reversible cause before treating: renal ultrasound for hydronephrosis from retroperitoneal or nodal disease, urinalysis and protein, review of nephrotoxic drugs and NSAIDs, hydration status and blood pressure.
2. If no obstruction and the edema is not overload, consider reducing to 3.7 GBq (50%) with close monitoring, or deferring one cycle and reassessing in 2-4 weeks after hydration.
3. Have an explicit discontinuation rule - for example, no further cycles if eGFR falls below about 30 or cytopenias reach grade 3-4.
4. Discuss benefit versus risk with the patient, including renal failure and secondary myelodysplasia/leukemia.

Amino acid infusion is the main lever. Co-infusion of lysine and arginine competitively blocks proximal tubular reabsorption of the peptide, reducing renal retention substantially, but it is also the part of the protocol most likely to hurt this particular patient.

Hazards here:

• Volume load. Standard regimens use 1 L or more over several hours. With a solitary kidney, eGFR 41 and new ankle edema, that can precipitate pulmonary edema.
• Hyperkalemia. Arginine-containing infusions raise potassium; he is already at 4.9 mmol/L.

Practical adjustments:

• Use a reduced volume (for example 500 mL) at a slower rate, with the peptide infused in the middle of the amino acid infusion.
• Check potassium, creatinine and weight on the day; have furosemide available; monitor blood pressure and urine output hourly.
• Encourage voiding frequently during and after the infusion to limit bladder and renal retention.
• Withhold NSAIDs and other nephrotoxins around the treatment.
• If he were to become anuric on dialysis, amino acids would be omitted and the infusion coordinated with the dialysis schedule.

Document the modified regimen and the reasoning - if the plan deviates from the institutional protocol, the note should explain why, so the next cycle does not simply default back to the full-volume infusion.

The dominant risk with Lu-177 is internal contamination from urine, not external exposure. Lu-177 is predominantly a beta emitter with modest 113 and 208 keV gamma emissions, so dose rates outside the patient are low and no barrier nursing is needed after discharge.

Advice:

• He can drive himself home. Sitting 130 km alone in a car is not a radiation hazard to anyone. Caution against drowsiness from antiemetics, and confirm he is fit to drive after the amino acid infusion.
• Use his own bathroom, sit to void, flush twice, wash hands thoroughly, and clean any splashes with gloves.
• Contain laundry and dispose of pads or soiled items as advised; if he has incontinence, plan ahead and use gloves.
• No need to avoid public transport or normal social contact, but limit prolonged close contact (under 1 m for hours) with pregnant women and young children for the first few days.
• Give a written card and an emergency contact; tell him to report inability to void.

Because he lives alone, no household restrictions are needed - which is worth saying explicitly, since patients often assume they must isolate. Reassure him and check his understanding with a teach-back.